KTX-105

N/A

Report date: 2025/01/26 16:29:43
NME

Base Information

Drug NameKTX-105
Drug Alias Nameselective STAT-3 degrader (Kymera Therapeutics)KTX-105
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSignal transducer and activator of transcription 3 inhibitorsUbiquitin-protein ligases modulators
TargetsSignal transducer and activator of transcription 3Ubiquitin-protein ligases
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, Anaplastic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKymera Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKymera Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, Anaplastic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A